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Abstract
Members of the family Coronaviridae, including the severe acute respiratory syndrome
coronaviruses (SARS-CoV-1 and SARS-CoV-2), Middle East respiratory syndrome coronavirus
(MERS-CoV) and seasonal human coronaviruses (HCoV-HKU1and HCoV-OC43), are highly
communicable respiratory viruses; SARS-CoV-1, SARS-CoV-2, and MERS can cause severe
disease, while seasonal human coronaviruses present with mild to moderate illness. Coronavirus
envelope spike (S) glycoproteins are involved in receptor binding and cell fusion, and are the
primary target for a neutralizing humoral response. The S protein is comprised of the S1 and S2
subunits; the S1 subunit contains the receptor-binding domain (RBD), while the S2 subunit
mediates fusion and cell entry. A conformational native S protein exists as a membrane-anchored
S protein trimer. Stabilized pre-fusion S protein ectodomain (S-2P) trimers have been developed
as vaccine candidates for SARS-CoV-1, SARS-CoV-2, and MERS-CoV (Corbett). Here, we
investigated the humoral immune response in COVID-19 patients using a serological assay based
on coronavirus S-2P trimers. Response kinetics were characterized, as well as associations
between the magnitude of the response and prior HCoV exposure with disease severity and
outcomes. Significant trends were observed that may be important in efficacious vaccine design
and serological surveillance.

Chapter 1 – Introduction
Research question
Here, we wished to determine the prevalence and magnitude of reactive antibodies to SARSCoV-2 and related coronaviruses in a cohort of patients enrolled at military treatment facilities
with suspected or confirmed COVID-19 to elucidate patterns between disease severity and the
humoral immune response.
Specific aims
Aim #1: Test sera from COVID-19 patients for SARS-CoV-2 and medically relevant HCoVreactive antibodies. Determine the kinetics of acute and convalescent sera immunoglobulins (Ig),
IgM and IgG, respectively.
Aim #2: Investigate associations between SARS-CoV-2-specific antibody titer and kinetics and
disease severity in COVID-19 patients.
Aim #3 Quantify the seroprevalence of HCoVs and investigate any disease severity associations
with cross-reactive SARS-CoV-2 antisera.
Significance
Viruses classified in the genus Betacoronavirus are known to cause acute respiratory disease in
human populations, including the ongoing COVID-19 pandemic that, at the time of writing, has
infected over 14.3 million persons globally and led to at over 600,000 deaths1. Current
knowledge suggests that bats are the wildlife hosts of several betacoronaviruses, implicating
zoonotic spillover as the source of betacoronavirus outbreaks. Primary surveillance measures
focus on nucleic acid detection of an active viral infection2, but serological surveillance of these
viruses is limited to a handful of emergency use authorized immunoassays. Understanding the
kinetics of the human immune response, as well as antibody ability to recognize conserved and

semi-conserved epitopes across betacoronaviruses permits a controlled investigation into SARSCoV-2 specific antibody responses and an understanding of how conserved epitopes across
betacoronaviruses promote cross reactive antibodies, facilitating rational vaccine design for
emerging zoonotic betacoronaviruses .

Chapter 2 – Background and Literature Review
Respiratory viruses pose a significant risk for respiratory infection and disease globally,
especially in infants, the elderly, and the immunocompromised3. Many viral respiratory
infections present with similar clinical symptoms, highlighting the need for precise and accurate
diagnostic capabilities to correctly diagnose and treat patients. Additionally, these viruses often
possess the ability to spread person-to-person via droplets and aerosols, and correct information
about the type of virus and mechanisms of spread can dictate the personal protective equipment
(PPE) that healthcare staff are required to use during treatment4 and protection of the public at
large. Indeed, of the four major viral pandemics of the 20th century, three were caused by
respiratory viruses capable of person-to-person transmission5. Understanding the pandemic
potential of known respiratory viruses has been a point of emphasis, and the global health
response surrounding the 2009 H1N1 outbreak shows that public health experts are learning
from lessons past6. Further, the recent emergence of novel coronaviruses underscores the
importance of heightened bio-surveillance activities to preemptively protect global health and
economic security.
In the 1960’s the first two coronaviruses, human coronavirus 229E (HCoV-229E) and
human coronavirus OC43 (HCoV-OC43), were discovered when investigating the common
cold7. The respiratory disease associated with these viruses is mild for most of the population but

can cause more severe disease for infants, the elderly, and persons with significant comorbidities.
In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in the Guangdong
province of Southeastern China, resulting in ~8,000 infections and ~800 deaths8. Subsequent
serum analysis from suspected SARS patients led to the discovery of human coronavirus NL63
(HCoV-NL63) and human coronavirus HKU1 (HCoV-HKU1), with disease presentation similar
to HCoV-229E and HCoV-OC439,10. In 2012, a novel viral isolate, MERS-CoV, was recovered
from a patient suffering from acute pneumonia at a hospital in Jeddah, Saudi Arabia11. Since the
initial discovery, MERS-CoV outbreaks continue annually, typically contained within the Middle
East, but instances of travel-associated and nosocomial spread have occurred with a case-fatality
rate of 34%12,13. In 2018, SARS-CoV and MERS-CoV were named by the WHO as blueprint
priority diseases as representatives of the broader class for research efforts due to the public
health risk stemming from their epidemic potential and lack of countermeasures14. In late 2019,
cases of severe acute respiratory distress identified in Wuhan, China, led to the discovery of a
new coronavirus, SARS-CoV-2, that has subsequently led to at least 14.3 million confirmed
cases and over 600,000 deaths worldwide, resulting in the WHO declaration of a public health
emergency of international concern due to the pandemic1.
In the United States, laboratory diagnostic measures for SARS-CoV-2 consists mainly of
PCR-based assays to detect copies of the viral genome2 in the right clinical setting, but also may
include serology. PCR-based assays allow for high-throughput diagnostics at a lower cost
compared to other methods, but due to limited kit availability and high demand, broader
screening initiatives are stalled. To better estimate the true disease burden at the time of the
outbreak, efficient contact tracing and testing should be performed for all suspected and exposed
cases of infection. However, although there are efforts attempting to increase such activities, this

possibility seems unlikely, as those who have been previously infected and have recovered will
unlikely carry copies of the viral genome that can be detected by these PCR-based assays.
Serology-based assays, primarily enzyme-linked immunosorbent assays (ELISAs), allow
for a larger window of opportunity for epidemiological studies on disease prevalence to occur,
due to the prolonged nature of humoral immunity. However, these assays can be costly and labor
intensive, and interpretations of these types of assays can be challenging due to antibody crossreactivity and the variety of virus antigens used between assays. Adaptation of an ELISA-based
assay onto a Luminex xMAP-based platform has previously been proposed as an alternative
method of serological analysis that could address the limitations of an ELISA-based platform15.
In this platform, antigens targeted in the humoral immune response would be tested in multiplex
for serological binding which allows for the determination of antibody cross-reactivity with more
precision than with ELISA.
Initial studies of the humoral response in COVID-19 patients suggest a nearly 100%
seroconversion rate by 2 weeks post-disease onset, as well as significantly improved sensitivity
in clinical diagnosis when combining PCR and serological-based assays within 1 week of disease
onset16. However, investigations of related betacoronovirus antibodies suggest a relatively shortlived immune response along with a potential for reinfection17,18. Additionally, preliminary
evidence in SARS-CoV-2 patients suggests differential immune responses depending on disease
severity, as well as an early reduction of IgG and neutralizing antibodies in the convalescent
phase19-21. A thorough understanding of the immune response can help inform rational vaccine
design, and patterns in the immune response can aid in the planning of surveillance activities.
Understanding the binding and neutralizing profile of antibodies generated from SARSCoV-2 infections can play an important role in rational vaccine design. Patterns of conserved

binding epitopes across species may elucidate the cross-neutralizing antibody response from one
vaccine relevant to protection against the next coronavirus to emerge. Additionally, conserved or
semi-conserved binding epitopes may elicit memory responses which can help structure crosssectional sero-surveys around the seasonal coronaviruses to better capture the true
seroprevalence of SARS-CoV-2 reactive antibodies.

Chapter 3 – Data and Methods
This study used a prospective, longitudinal cohort to analyze COVID-19 disease among
enrollees from five military treatment facilities (MTFs) across the continental United States. The
MTFs included Walter Reed National Military Medical Center (WRNMMC) (Bethesda, MD),
Brooke Army Medical Center (BAMC) (San Antonio, TX), Navy Medical Center San Diego
(NMCSD) (San Diego, CA), Madigan Army Medical Center (MAMC) (Tacoma, WA), and Fort
Belvoir Community Hospital (FBCH) (Fort Belvoir, VA). Participants were drawn from
populations that travel to or reside in different SARS-CoV-2 affected regions within the United
States, including civilians and military personnel. Enrollments were without regard to age, race,
and gender. Inclusion criteria included laboratory-confirmed presence of a respiratory infection
at a participating MTF, were a person under investigation for a pathogen of interest (PUI) as
specified by the Centers for Disease Control (CDC) guidelines, or were asymptomatic and/or had
tested negative for a respiratory pathogen but were considered to have/had a recent exposure to
the pathogen of interest.
The data source for the age, sex, race, military affiliation, military branch, enrollment
site, smoking status, vaping status, obesity, diabetes, chronic cardiac disease, chronic pulmonary
disease, hospitalization status, disease severity and sapling dates were determined from the

patient’s enrollment data via a standardized enrollment form. PCR data was generated using the
Panther Fusion SARS-CoV-2 real-time (RT) PCR assay. Mean fluorescent intensity, the raw
readout of the SARS-CoV-2 IgG and IgM result, and HCoV result were determined by MMIA.
The variables collected in this study included age, sex, race, military affiliation, military
branch, enrollment site, smoking status, vaping status, obesity, the presence of diabetes, chronic
cardiac disease, or chronic pulmonary disease, SARS-CoV-2 PCR diagnosis, hospitalization
status, disease severity, date(s) sampled, microsphere-based multiplex immunoassay (MMIA)
mean fluorescent intensities (MFI) for both IgG and IgM for SARS-CoV-2, SARS-1, MERS,
HKU1, and OC43 spike proteins, SARS-CoV-2 IgG MMIA result, SARS-CoV-2 IgM MMIA
result, and HCoV MMIA result.
Participants with missing SARS-CoV-2 diagnostic tests were removed from the data set,
and remaining participants were grouped into two groups based upon PCR result. Overall
demographic summaries for the categorical variables were constructed. Continuous variables
from each group were used to generate boxplots. These variables were tested for independence
employing the Chi-Squared Test for Independence and the Fisher’s Exact Test to elucidate
potential interactions between categorical variables and PCR result. The PCR positive group was
further tested employing the Chi-Squared Test for Independence and the Fisher’s Exact Test to
incorporate interactions with disease severity, characterized by hospitalization status, limitation
of physical activity, and the requirement and type of therapeutic oxygen. Finally, the SARSCoV-2 IgG titer was investigated in relation to disease severity using both an Independent
Samples T-Test and an ANOVA.
Generalized Estimating Equations were performed on SARS-CoV-2 IgG and IgM MFI
values in order to detect seroconversion as well as evidence of waning immunity. The mean days

post symptom onset for PCR positive, IgG positive, IgM subgroups was analyzed using an
Independent Samples T-test in order to detect a difference in means between the two groups.
Finally, the IgG MFI values for each of the coronavirus antigens were plotted in order to find
patterns of reactivity throughout the time-course.

Chapter 4 – Results
Study population
Summaries of participant information grouped by PCR status can be found in Table 1.
The study population was diverse: the average age of study participant was 45.8 years with a
standard deviation of 15.8, a minimum age of 13.5 and a maximum age of 84.5. Twenty-two
participants were Black, fifty-one White, twenty-eight Hispanic, five native Hawaiian, nine
Others, and one had a missing value. There were sixty-six male and fifty female participants.
Thirty-nine participants were active duty members of the military, thirty-six were retired
military, thirty-nine were military dependents, one was a civilian and one had a missing value.
Of the military associates, fifty-four were affiliated with the Army, twenty-nine Navy, nine
Marines, twenty Air Force, one Coast Guard, one listed as other, and one had a missing value.
Seventy-two participants had a recorded SARS-CoV-2 PCR positive result, while thirty-four
were recorded as negative and ten results were missing. Sixty-six participants were treated as
outpatients, forty-three were inpatient, and seven had missing values. Of all of the participants,
thirty-four were listed as outpatient without limited physical activity, thirty-two were listed as
outpatient with limited physical activity, sixteen as inpatient without the requirement of
supplemental oxygen, twenty-three as inpatient with non-invasive oxygen required, four as
inpatient requiring ventilation, and seven with missing severity levels. Six of the participants

were active smokers, thirty-three were former smokers, seventy-five never smoked, and two had
missing values. Two participants were active vapers, seven had previously vaped, one-hundredfour had never vaped, and three had missing values. Twenty-two participants were obese, while
ninety-three participants were not, and one had a missing value. One-hundred-two participants
were not diabetic, thirteen were, and one was missing. One-hundred-six participants reported no
chronic cardiac disease, while nine did with one missing. One-hundred-ten participants reported
no chronic cardiac disease, while five did with one missing. The average collection date of
samples post symptom onset of was 33.5 days with a standard deviation of 19.0, a minimum of
one, and a maximum of one-hundred-three. Boxplots showing the distributions of age and days
post symptom onset at the time of sampling can be found in Figure 1.

Table 1. Categorical Variables of Study Participants separated into PCR negative and PCR
positive groups.

A)

B)

Figure 1. Boxplots of the continuous variables separated by PCR status. A) Distribution of
Age and B) days post symptom onset at the time of sampling.

Chi-Squared Tests for Independence and Fisher’s Exact Tests were used to determine any
associations between categorical variables (Table 2). For the entire population, disease diagnosis
was associated with the site of enrollment (p<0.0001), due to the WRNMMC facility only
enrolling PCR positive patients. Among the PCR positive participants disease severity was
associated with race (p=0.01), military affiliation (p=0.0005), site of enrollment (p<0.0001),
chronic cardiac disease (p=0.038), age group (p=0.0372), and obesity (p=0.012), and chronic
cardiac disease was associated with chronic pulmonary disease (p=0.0136). As expected, military
affiliation was confounded by age, with older participants primarily grouped into the retired
military subset.

Table 2. Categorical variables with significant association. A two-tailed Chi-Squared Test for
Independence was used to detect associations between categorical variables. Fisher’s Exact Tests
were used when the Chi-Squared assumptions were not met.

Main results of Antibody Testing
To investigate patterns of Ig decay, two methods were used. First, the difference in days
post symptom onset for 20 IgM negative and 95 IgM positive samples collected in PCR positive,
and IgG positive participants was investigated using an Independent Samples T-Test. Equal
variance was observed so a Pooled analysis was used. The mean difference was 7.15 days greater
in IgM negative samples (p=0.0368), indicating significant IgM decay relative to IgG. Next, a
Generalized Estimate Equation was used to predict the factor of IgM decay over time.
Significant IgM decay was detected (p=0.0007), with a predicted loss of 130 MFI per day. A
Generalized Estimate Equation was again used to determine IgG decay over time. Although the
equation predicted IgG decay over time, the factor was determined to be non-significant
(p=0.09).

Table 3. Statistical Analysis of Immune Kinetics. A) Independent Samples T-Test to detect
differences in mean days post symptom onset between IgM negative and IgM positive groups. B)
Generalized Estimate Equation to detect decay in IgM titer (measured with MFI) over time. C)
Generalized Estimate Equation to detect decay in IgG titer (measured with MFI) over time.

Due to limitations in the samples collected, investigations into the timing of
seroconversion were not possible. However, trends in the time-course could be analyzed for two
of the three relevant participants (Figure 2). In both persons, an atypical immune response
involving IgG and IgM peaking together was observed at or shortly after ten days. More
investigation into the kinetics of other participants is required to determine any relevant patterns.

Figure 2. Graphs of immune kinetics. Time-course graphs for participants S00-0014 (top) and
S00-0022 (bottom). Mean fluorescent intensity is used as a measure of Ig titer. In both graphs,
IgG is represented in red, while IgM is in blue.

Two methods were used to investigate differences in SARS-CoV-2 IgG magnitudes with
disease severity (Table 4). First, an Independent Samples T-Test was used to compare the mean
MFI values between in- and outpatient participants at least 28 days post symptom onset. Unequal
variance was observed between the two groups, so a Satterthwaite analysis was used. The mean
MFI value for the hospitalized group was 11048.8 units higher than in the outpatient group,
indicating a significantly higher IgG magnitude (p<0.0001). Next, a one-way ANOVA was used
to compare the mean MFIs between severity categories. Again, significant differences were
observed (p<0.0001). Unsurprisingly, the more severe groups (requiring inpatient treatment) had
higher MFI values than did the less severe groups, however there were no observed differences
within the outpatient or inpatient severity subsets.

Table 4. Statistical analysis of SRS-2 IgG magnitude by disease severity groups. (A) Pooled,
independent samples T-Test for differences in SARS-CoV-2 IgG MFI by hospitalization status.
(B) One-way ANOVA comparing differences in SARS-CoV-2 IgG MFI by disease severity.

Other results
Investigations into the impact of prior HCoV exposure on disease severity were not
possible due to an extremely high HCoV IgG prevalence in the study population. However,
interesting patterns from the two time-course patients were observed. In both participants, OC43reactive antibodies are detected at the first time point in relatively high-titers and climb
throughout the time-course. Additionally, reactive antibodies to SARS-1 and MERS climb in
nearly identical patterns that follow the growth of SARS-CoV-2 specific antibodies.

Figure 3. Graphs of IgG kinetics across viral species. Time-course graphs for participants
S00-0014 (top) and S00-0022 (bottom). Mean fluorescent intensity is used as a measure of IgG
titer. In both graphs, SARS-CoV-2 is represented in red, SARS-1 in olive, MERS in charcoal,
HKU1 in green, OC43 in blue, and mock in purple.

Chapter 5 – Discussion
In this project, I sought to investigate relevant demographic and clinical characteristics in
a prospective cohort of patients enrolled at MTFs and their association with COVID-19 disease
severity, as well as the important humoral immune characteristics as they relate to COVID-19.
Unsurprisingly, many of the characteristics, such as age, race, obesity, and chronic cardiac
disease, were confirmed to be associated with disease severity as reported elsewhere22-26.
Significant trends were discovered in the immune responses of this cohort that may
inform public health practice. First, canonical IgM decay was observed, whereas a non-canonical
primary Ig response occurred where IgM and IgG titers rose simultaneously. This pattern, along
with high levels of OC43 IgG that rose alongside SARS-CoV-2-specific IgG, indicates a possible
anamnestic response triggered by SARS-CoV-2 exposure may be accelerating the temporal
detection of SARS-CoV-2 reactive IgG. However, limitations in sample size do not allow for a
determination of significance. Additionally, a higher magnitude IgG response was detected in
patients with more severe disease. Recent studies have found a similar trend and suggested that
the association between severe COVID-19 coincided with viral infections of the lower
respiratory tract, which were hypothesized to require higher levels of antibody in order to reach
infected lung tissue27. Together, this information suggests that the elderly and persons with
significant comorbidities should be prioritized for measures designed to limit SARS-CoV-2
exposure to minimize the number of severe COVID-19 cases.
This project had a few limitations that are important to discuss. Most importantly, more
samples from more participants would allow for a more thorough understanding of the
associations above. Trends from the two time-course participants may be highlighted or muted
with more time-course participants. Additionally, the DoD-eligible and DoD-beneficiary

population in this study might not be reflective of the overall United States population.
Specifically, the male to female ratio is inconsistent with the US population, and smokers and
persons with significant comorbidities were underrepresented in the cohort. However, some
trends found in the general population were also found within this cohort, leading me to believe
that this study can be generalizable across the US.
These results raise more questions about public health policy moving forward. Prior viral
exposure and disease severity should be considered when initiating a vaccine campaign.
Currently, there is no evidence suggesting a low magnitude antibody response provides
protective immunity28. The neutralizing ability of these sera will need to be investigated prior to
vaccination determinations. Additionally, evidence of an anamnestic response to other
coronaviruses contradicts the current dogma surrounding the short-lived nature of coronavirus
immunity. Investigations into the memory response generated by COVID-19 survivors will play
a pivotal role in informing population vaccine planning. Finally, future sero-surveillance projects
should consider the anamnestic response when planning sampling efforts. Persons who had lesssevere SARS-CoV-2 infections may have lower-than-detectable levels of circulating antibody
that may be increased when exposed to seasonal coronaviruses. Sampling measures that
prioritize sampling during cold seasons may produce results that are more reflective of the true
seroprevalence in any given population.
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